Johnson & Johnson and Pfizer are two major healthcare players with distinct business models, making them attractive but different investment options in 2026. Johnson & Johnson reported a 6% increase in fiscal 2025 sales to $94.2 billion, with net income boosted by a $7 billion reversal of its talc reserve. The company operates in two segments: Innovative Medicine and MedTech, generating $60.4 billion and $33.8 billion in sales, respectively. Its debt-to-equity ratio stood at 0.59x, and it raised its 2026 sales outlook to $100.8 billion to $101.4 billion, marking its 64th consecutive annual dividend increase.
Pfizer, on the other hand, focuses on biopharmaceuticals and reported a net loss of $248 million in the second quarter of 2026 due to $4.3 billion in non-cash intangible asset impairments. Its revenue rose about 3% to $15.0 billion in the same quarter. Pfizer expects significant revenue reductions from patent expirations between 2026 and 2030 but offers a higher dividend yield of about 6%, compared to Johnson & Johnson's 2%. The company's debt-to-equity ratio is 0.75x, and it recently acquired Metsera to bolster its obesity treatment pipeline.
Johnson & Johnson faces risks from Medicare price negotiations on drugs like XARELTO and STELARA, as well as ongoing talc litigation. It has proposed a $5.5 billion settlement for talc-related claims, pending plaintiff participation. Meanwhile, Pfizer's revenue is at risk from patent expirations and regulatory exclusivity losses, though its acquisition of Metsera could mitigate some of these impacts. Valuation-wise, Pfizer trades at lower multiples than Johnson & Johnson on both forward earnings and sales.
While Johnson & Johnson appears to be the stronger buy due to its diversified revenue streams and consistent performance, Pfizer's higher dividend yield and strategic acquisitions make it a compelling option for income-focused investors. Both stocks should be considered as part of a broader healthcare investment strategy, with a long-term holding perspective.